Clinical Trial Update: Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib [Phase 2]

View source ↗

Summary

A Phase II biomarker study comparing upfront combination therapy with dabrafenib plus trametinib versus sequential combination after monotherapy in melanoma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-02-18